- Joined
- Sep 22, 2008
- Messages
- 85,006
- Points
- 113
JV first, then after knowing secrets, go on your own at half the cost as no need for initial expensive research.
Pfizer to develop new vaccines on its own using mRNA technology — report
Manojna Maddipatla
/
Reuters
March 23, 2021 20:00 pm +08
-A
+A
BENGALURU (March 23): Pfizer Inc plans to tap mRNA technology to make new vaccines for other viruses following the success of its Covid-19 shot, which was developed jointly with German partner BioNTech SE, the Wall Street Journal (WSJ) reported on Tuesday.
The drug maker said it was ready to pursue Messenger RNA (mRNA) on its own following its experience in the past year working on the Covid-19 vaccine, the WSJ reported, citing an interview with Pfizer chief executive officer Albert Bourla.
It did not, however, disclose any details about the viruses it was targeting.
Pfizer and BioNTech did not immediately respond to Reuters' requests for comment.
BioNTech's US-listed shares were down 1.1% before the opening bell.
Pfizer-BioNTech and Moderna's Covid-19 vaccines, authorised for emergency use in the United States, use mRNA technology.
Vaccines developed using mRNA work by inserting synthetic mRNA that instructs cells to make a pathogen's proteins or protein bits, spurring the immune system into action.
The success of the technology is prompting drug developers to consider its use in other areas of medicine beyond vaccines such as cancer treatments, attracting billions of dollars in investment.
Other companies such as Germany's CureVac NV, Gilead Sciences, Sanofi, and Translate Bio are also developing mRNA-based vaccines and therapeutics.
Last March, Pfizer announced a deal with BioNTech to use the Mainz-based company's mRNA-based platform to develop a vaccine against the coronavirus, extending the companies' existing partnership to develop flu shots.
Bourla said Pfizer has now developed its own expertise in developing mRNA vaccines, the WSJ report said.
Pfizer's current vaccine business, which includes its pneumonia vaccine Prevnar 13, brought in nearly US$6.58 billion or about 16% of the drug maker's total sales last year.
Pfizer to develop new vaccines on its own using mRNA technology — report
Manojna Maddipatla
/
Reuters
March 23, 2021 20:00 pm +08
-A
BENGALURU (March 23): Pfizer Inc plans to tap mRNA technology to make new vaccines for other viruses following the success of its Covid-19 shot, which was developed jointly with German partner BioNTech SE, the Wall Street Journal (WSJ) reported on Tuesday.
The drug maker said it was ready to pursue Messenger RNA (mRNA) on its own following its experience in the past year working on the Covid-19 vaccine, the WSJ reported, citing an interview with Pfizer chief executive officer Albert Bourla.
It did not, however, disclose any details about the viruses it was targeting.
Pfizer and BioNTech did not immediately respond to Reuters' requests for comment.
BioNTech's US-listed shares were down 1.1% before the opening bell.
Pfizer-BioNTech and Moderna's Covid-19 vaccines, authorised for emergency use in the United States, use mRNA technology.
Vaccines developed using mRNA work by inserting synthetic mRNA that instructs cells to make a pathogen's proteins or protein bits, spurring the immune system into action.
The success of the technology is prompting drug developers to consider its use in other areas of medicine beyond vaccines such as cancer treatments, attracting billions of dollars in investment.
Other companies such as Germany's CureVac NV, Gilead Sciences, Sanofi, and Translate Bio are also developing mRNA-based vaccines and therapeutics.
Last March, Pfizer announced a deal with BioNTech to use the Mainz-based company's mRNA-based platform to develop a vaccine against the coronavirus, extending the companies' existing partnership to develop flu shots.
Bourla said Pfizer has now developed its own expertise in developing mRNA vaccines, the WSJ report said.
Pfizer's current vaccine business, which includes its pneumonia vaccine Prevnar 13, brought in nearly US$6.58 billion or about 16% of the drug maker's total sales last year.
